Stephen Donnelly (Wicklow, Independent) | Oireachtas source

What lobbying can be done in the medium-term on the basis that this is not a normal product, but an addictive drug with significant health consequences? What conversation can be had in Europe to the effect that, while we agree with the principle for good market reasons, this is a highly unusual product?